Related Experiment Video
Updated: Oct 3, 2025
10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
18.6K
Emerging Treatments in Schizophrenia.
Christoph U Correll1,2,3, Anissa Abi-Dargham4, Oliver Howes5
1Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, New York.
The Journal of Clinical Psychiatry
|February 16, 2022
Summary
New schizophrenia medications targeting trace amine-associated, muscarinic, and serotonergic receptors show promise. These non-dopamine blocking agents may offer improved efficacy and tolerability for patients with schizophrenia.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Current antipsychotics, effective for schizophrenia, primarily block dopamine D2 receptors, leading to incomplete symptom resolution and side effects.
- Schizophrenia's pathophysiology is complex, involving widespread brain circuit alterations beyond simple dopamine dysregulation.
Purpose of the Study:
- To explore novel therapeutic targets beyond dopamine D2 receptor blockade for schizophrenia treatment.
- To review emerging drug candidates with different mechanisms of action for schizophrenia.
Main Methods:
- Review of current literature on schizophrenia treatment mechanisms and drug discovery efforts.
- Analysis of positive Phase 2 trial results for novel antipsychotic candidates.
Main Results:
- Positive Phase 2 trial data for ulotaront (TAAR1 agonist), KarXT (M1/M4 agonist), and pimavanserin (5-HT2A agonist/antagonist) in schizophrenia symptom domains.
- These agents demonstrate efficacy without relying on dopamine D2 receptor blockade.
Conclusions:
- Emerging non-D2 blocking medications show potential to significantly alter schizophrenia treatment paradigms.
- These novel therapies may offer improved outcomes for patients unresponsive or intolerant to existing treatments.
Related Concept Videos
01:28Drug Therapy
111
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
111
01:26Psychosis: Goals of Pharmacotherapy
236
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
236
01:28Psychosis and Antipsychotic Drugs: Overview
509
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
509
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
1.1K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
1.1K
01:29Psychological and Sociocultural Causes of Schizophrenia
221
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
221
01:23Antidepressant Drugs: MAOIs and Other Agents
405
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
405